| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 Part 3 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 Part 3 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 Part 3 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
MetaVia Inc.$1.42
-0.01 (-0.69%)
Market Cap
19.88 M
EPS
-6.02
P/E Ratio
-
Value Trade
896.03 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.10 M
Operating CF
-4.26 M
Total Assets
14.39 M
Total Liabilities
5.32 M
Equity
9.07 M
D/E Ratio
12,345
229.06 %
Week
140.63 %
1 Month
143.67 %
3 Month
-48.68 %
6 Month
-99.95 %
5 Year
-100 %
All Time
Cash Data
Cash Position
13.73 M
Monthly Burn
1.42 M
Runway
7.2 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
133.20 K
52 Week Range
0.97 - 19.03
% held by Insiders
34.8 %
% held by Institutions
1.3 %
Enterprise Value
6.35 M
Total Shares
5.16 M
Short %
10.23 %
Float Shares
3.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MetaVia Inc.
406Total events
6Upcoming
118Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▲Enrollment MilestoneDA-1726Trial
Subscribe to view catalyst details
TBD
▲Enrollment CompleteDA-1726Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-07 | Vanoglipel (DA-1241) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-06-07 | Vanoglipel (DA-1241) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-06-07 | Vanoglipel (DA-1241) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DA-1726 | obesity | Phase 1 | 2026-06-08 | up to 9.1% Mean Body Weight Reduction at Day 54 | MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential Read More | |
DA-1726 | obesity | Phase 1 | 2026-06-08 | up to 9.1% Mean Body Weight Reduction at Day 54 | MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential Read More | |
DA-1726 | obesity | Phase 1 | 2026-06-08 | up to 9.1% Mean Body Weight Reduction at Day 54 | MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MTVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MTVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MTVA▲ +10.9%on this news· ran to +24% by day 3
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
MetaVia Inc. has announced the successful completion of dose titration in Part 3 of its Phase 1 clinical trial for DA-1726, aimed at treating obesity. All active patients have reached their highest target doses, reinforcing the drug's favorable tolerability. The company anticipates reporting topline data in the fourth quarter of 2026, showcasing DA-1726's potential for weight loss and metabolic benefits.
Read more →MTVAMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia Inc. has announced its participation in the upcoming Life Sciences Virtual Investor Forum, where CEO Hyung Heon Kim will present the company's innovative pipeline targeting obesity and metabolic diseases. The forum, set for June 24, 2026, allows real-time interaction between investors and company management. MetaVia is developing two key therapeutic candidates: DA-1726, a dual agonist showing potential for significant weight loss, and vanoglipel, which offers unique benefits for metabolic disorders and liver health. This presentation aims to engage investors and provide insights into their clinical advancements.
Read more →MTVA▼ -13.6%on this news· ran to -26% by day 1
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
MetaVia Inc. presented new data at the ADA 2026 Scientific Sessions, showcasing promising results for DA-1726, a dual agonist for obesity treatment, which achieved significant weight loss without plateau. Additionally, vanoglipel demonstrated synergistic effects when combined with other therapies in preclinical models for metabolic diseases. The findings support ongoing development and potential combination strategies.
Read more →MTVA▼ -8.6%on this news· ran to -29% by day 3shared move
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia Inc. will present its pipeline of innovative obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026. The company is focused on transforming cardiometabolic diseases with promising candidates such as DA-1726, an oxyntomodulin analogue, and vanoglipel, a GPR119 agonist. Both therapies have shown significant potential in clinical studies for weight loss, glucose control, and liver health. Attendees will have the opportunity to ask questions during and after the presentation.
Read more →MTVA▲ +12.5%on this news
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the...
MetaVia Inc. presented promising Phase 1 results for DA-1726 at the EASL Congress 2026, highlighting significant weight loss and liver-related improvements in obese participants. The 48 mg cohort achieved a mean body weight reduction of 9.1% without evidence of plateau. The findings support further evaluation of DA-1726 for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MTVA▲ +12.5%on this news
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau E
MetaVia Inc. presented promising Phase 1 data for DA-1726 at the EASL Congress 2026, revealing a mean body weight reduction of 9.1% in the 48 mg cohort by Day 54. The compound, a dual GLP-1 and glucagon receptor agonist, demonstrated favorable safety and tolerability, with no serious adverse events reported. Additionally, exploratory assessments indicated early improvements in liver-related parameters, highlighting DA-1726's potential in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). Ongoing studies aim to evaluate longer-term dosing strategies and optimize treatment durability.
Read more →MTVA▲ +53.7%on this news
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
MetaVia Inc. announced a peer-reviewed publication validating the anti-fibrotic potential of vanoglipel, a GPR119 agonist. The study demonstrated that vanoglipel reduced liver fibrosis and supported findings from a Phase 2a clinical trial, where patients showed significant improvements in liver health markers. The publication emphasizes the dual metabolic and anti-fibrotic effects of GPR119 agonism.
Read more →MTVAMetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
MetaVia Inc. announced that three late-breaking abstracts featuring its cardiometabolic assets, DA-1726 and vanoglipel, have been accepted for presentation at the ADA 2026 Scientific Sessions. DA-1726 is currently in a Phase 1 study targeting obesity, while vanoglipel is being explored for its effects on metabolic diseases. The presentations will take place on June 7, 2026, in New Orleans.
Read more →MTVAMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial...
MetaVia Inc. reported its first quarter 2026 financial results, highlighting the successful dosing of the first patient in Phase 1 Part 3 of its DA-1726 clinical trial. The trial is evaluating higher doses aimed at obesity treatment, building on previous positive results. The company anticipates data readout in Q4 2026, while also addressing its financial performance, including a net loss of $3.8 million.
Read more →MTVAMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update 48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Li
MetaVia Inc. has reported its first-quarter financial results for 2026, highlighting significant progress in its clinical trial for DA-1726, a treatment for obesity. The trial has successfully dosed its first patient under a higher dose regimen, building on previously reported weight loss and glucose control effectiveness. The company anticipates reporting further data by the fourth quarter of 2026 and has noted that the current financial support is essential for this ongoing study. However, MetaVia also faces challenges, including continued net losses and the uncertainty of future clinical trial outcomes.
Read more →MTVAMetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
MetaVia Inc. announced that its dual agonist DA-1726 has been accepted for a late-breaking poster presentation at the EASL Congress 2026. The presentation will focus on DA-1726's safety, tolerability, and pharmacodynamics in treating obesity. The company is currently conducting a Phase 1 study to optimize dosing and assess tolerability, with results expected later this year.
Read more →MTVA▲ +18.5%on this news
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
MetaVia Inc. has initiated dosing for the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual agonist for obesity treatment. This phase will evaluate two titration strategies over 16 weeks, aiming to optimize dosing and tolerability. Early results indicate significant weight loss and metabolic improvements, with data expected in late 2026.
Read more →MTVAMetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia Inc. reported positive financial results for 2025 and provided updates on its clinical programs. The company highlighted promising Phase 1 data for DA-1726, demonstrating significant weight loss and improved glucose control. Additionally, MetaVia announced plans for a Phase 1 Part 3 study and confirmed financial stability through a recent public offering.
Read more →MTVAMetaVia Inc. Transforming Cardiometabolic Diseases Investor Presentation March 2026 www.metaviatx.com Nasdaq: MTVA 2 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of
MetaVia Inc. presented promising data on Vanoglipel, an investigational treatment for cardiometabolic diseases, at the EASL 2025 conference. The Phase 2a trial showed that Vanoglipel significantly reduced HbA1c levels in patients with Type 2 Diabetes, indicating improved glucose control. Additionally, it displayed a favorable safety profile, with no serious adverse events leading to discontinuation of the treatment. The combination of Vanoglipel with Sitagliptin further enhanced glucose control, suggesting a strong therapeutic potential for managing metabolic conditions.
Read more →MTVAMetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia Inc. has received IRB approval for Phase 1 Part 3 trials of DA-1726, a dual agonist targeting GLP-1 and glucagon receptors. The trial will evaluate two dosing strategies over 16 weeks in obese adults. Previous studies indicated significant weight loss and improved metabolic parameters, reinforcing DA-1726's potential as a leading obesity treatment.
Read more →MTVAMetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia Inc. has announced an extensive global patent portfolio for vanoglipel, its GPR119 agonist, which includes 48 granted and pending patents across multiple countries. This portfolio ensures protection until 2035 and covers various therapeutic applications for metabolic and liver diseases. The company emphasizes the strategic importance of this intellectual property in maximizing vanoglipel's value.
Read more →MTVAMetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Inc. has announced a robust global intellectual property portfolio for its lead asset, DA-1726, aimed at treating obesity and metabolic disorders. The portfolio includes 39 granted and pending patents, providing protection until 2041. Recent clinical data indicate promising results, including significant weight loss and improvements in metabolic health. The company plans further studies to confirm DA-1726's efficacy.
Read more →MTVAMetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
MetaVia Inc. announced promising results from its collaboration with Syntekabio, confirming that its GPR119 agonist, vanoglipel, effectively targets inflammatory diseases and cardiometabolic disorders. The AI-driven analysis supports ongoing development for metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes (T2D). Positive Phase 2a clinical study results further bolster confidence in vanoglipel's therapeutic potential.
Read more →MTVA▼ -5.8%on this news
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Inc. has completed its underwritten public offering, raising approximately $9.3 million, which includes the full exercise of the underwriter's over-allotment option. The offering comprised shares of common stock and warrants aimed at supporting the clinical development of DA-1726, a treatment for obesity. MetaVia plans to utilize the proceeds for working capital and general corporate purposes. The company is focused on advancing its cardiometabolic disease treatments and has shown promising results in preliminary clinical trials.
Read more →MTVA▼ -39.1%on this newsshared move
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia Inc. has announced the successful pricing of its underwritten public offering, aiming to raise approximately $8.1 million. The offering includes common stock and Series C and D Warrants priced at $3.10 each. The company intends to use the proceeds to further develop its clinical candidate DA-1726, aimed at treating obesity. Additionally, there exists a financial opportunity for up to $24 million more from potential future warrants exercise. The anticipated closing of the offering is set for January 16, 2026, pending customary conditions.
Read more →MTVA▼ -8.7%on this news
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
MetaVia Inc. announced positive results from its Phase 1b clinical trial of DA-1726, showing significant weight loss, reductions in waist circumference, and improvements in glucose control. The trial demonstrated a 9.1% average weight loss and a 23.7% reduction in liver stiffness by Day 54. The drug's favorable safety profile and metabolic benefits highlight its potential as a leading treatment for obesity.
Read more →MTVAMetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
MetaVia Inc. will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference from January 8-10 in Park City, Utah. The company's teams will engage with industry peers while promoting their innovative treatments for cardiometabolic diseases. MetaVia is developing DA-1726 and vanoglipel, both showing promising results in clinical trials.
Read more →MTVA▲ +11.6%on this news
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
MetaVia Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement as of December 19, 2025. The company is focused on developing treatments for cardiometabolic diseases, including DA-1726 for obesity and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis. Both candidates have shown promising results in clinical trials.
Read more →MTVA▼ -20.1%on this news
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
MetaVia Inc. has announced a 1-for-11 reverse stock split effective December 4, 2025, to comply with Nasdaq listing requirements. The split will reduce the number of outstanding shares from approximately 25.4 million to about 2.3 million. The company continues to focus on developing treatments for cardiometabolic diseases, including DA-1726 and vanoglipel.
Read more →MTVA▲ +6.8%on this news
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
MetaVia Inc. announced positive Phase 2a trial results for vanoglipel (DA-1241), a GPR119 agonist targeting metabolic dysfunction-associated steatohepatitis (MASH). The trial showed significant improvements in glucose control, liver health, and lipid profiles after 16 weeks of treatment. The findings were presented at the AASLD The Liver Meeting 2025, reinforcing vanoglipel's potential as a dual-action therapy.
Read more →MTVA▼ -15%on this newsshared move
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Inc. reported its third quarter 2025 financial results, highlighting the initiation of a Phase 1 clinical trial for DA-1726, which aims to treat obesity. The trial's early data suggests promising weight loss and safety profiles. The company also plans to present full Phase 2a results for vanoglipel at an upcoming liver disease meeting. MetaVia has $14.3 million in cash to support its operations through 2026.
Read more →MTVA▼ -15%on this newsshared move
December 2023 NASDAQ: NRBO 1 November 2025 MetaVia Inc. NASDAQ: MTVA 2 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act o
MetaVia Inc. (NASDAQ: MTVA) provided an update on its therapeutic pipeline, highlighting promising results for DA-1726 and Vanoglipel in weight loss and metabolic conditions. DA-1726 exhibited notable weight loss and improvements in glucose levels, without significant safety concerns. Vanoglipel met its primary efficacy endpoints in a Phase 2a trial and displayed favorable effects on liver health markers. The company is looking to expand partnerships for further development.
Read more →MTVA▼ -7.4%on this news· ran to -26% by day 3shared move
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
MetaVia Inc. announced new Phase 1 and pre-clinical data for DA-1726, a dual agonist targeting obesity, at ObesityWeek 2025. The Phase 1 trial indicated favorable safety, tolerability, and significant weight loss without dose titration. Pre-clinical results showed DA-1726's superior lipid-lowering effects compared to pemvidutide, reinforcing its potential as an effective obesity treatment.
Read more →MTVAMetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
MetaVia Inc. announced that an abstract on Vanoglipel (DA-1241), a GPR119 agonist, has been accepted for a poster presentation at the AASLD Liver Meeting 2025. The drug has shown potential benefits in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes, demonstrating positive effects on glucose and lipid metabolism. The presentation will take place from November 7-11, 2025, in Washington, D.C.
Read more →MTVAMetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
MetaVia Inc. announced that two abstracts on DA-1726, a dual agonist for obesity treatment, will be presented at ObesityWeek 2025. The drug has shown promising results in pre-clinical studies, outperforming existing therapies like semaglutide. DA-1726 is designed for weekly subcutaneous administration and aims to enhance weight loss and metabolic health.
Read more →MTVA▲ +5.2%on this news
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
MetaVia Inc. will present at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025. CEO Hyung Heon Kim and CFO Marshall H. Woodworth will provide an overview and engage in one-on-one meetings with institutional investors. The company is focused on developing innovative treatments for cardiometabolic diseases, including DA-1726 and DA-1241.
Read more →MTVAMetaVia to Present at Upcoming Investor and Industry Conferences
MetaVia Inc. has announced its participation in upcoming investor and industry conferences. The company is focused on developing treatments for cardiometabolic diseases, including DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis. Both candidates have shown promising results in clinical studies, indicating their potential effectiveness in weight loss and metabolic health.
Read more →MTVAMetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-172
MetaVia Inc. reported its financial results for the second quarter of 2025, highlighting the dosing of the first patient in the Phase 1 trial for DA-1726 aimed at obesity treatment. The company also announced a collaboration with Syntekabio to explore additional indications for DA-1241, a promising GPR119 agonist. MetaVia's financial position remains strong, with $17.6 million in cash expected to fund its operations into 2026. Despite reporting a net loss of approximately $7.7 million, the company showcased optimistic clinical progress and strategic partnerships.
Read more →MTVAMetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial...
MetaVia Inc. reported its second quarter 2025 financial results, highlighting significant progress in clinical trials for its obesity treatment DA-1726. The company has dosed the first patient in an 8-week Phase 1 trial and expects top-line data in Q4 2025. Additionally, a collaboration with Syntekabio aims to explore further indications for DA-1241. Despite a net loss of $4.0 million, the company is well-capitalized to fund operations into 2026.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 August 2025 MetaVia Inc. NASDAQ: MTVA 2 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
MetaVia Inc. (MTVA) reported promising results for its obesity treatment candidates during recent presentations. DA-1726, currently in a Phase 1 study, exhibited strong weight loss results and effective glycemic control, particularly at a 32 mg dose. Additionally, the ongoing clinical trials indicate a favorable safety profile, with no severe treatment-related adverse events observed. The company is also exploring partnerships for its development pipeline, which includes DA-1241, targeting liver-related diseases.
Read more →MTVAMetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
MetaVia Inc. has extended the 48 mg multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726 for obesity treatment from 4 to 8 weeks. This extension aims to assess longer-term efficacy and safety, with top-line data expected in Q4 2025. Initial results indicate DA-1726 may offer superior tolerability compared to existing GLP-1 therapies.
Read more →MTVAMetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 Partnership Leverages Syntekabio's DeepMatcher Platform to Expand the Therapeutic Potential of MetaVia's Oral GPR119
MetaVia Inc. has announced a research collaboration with Syntekabio to explore additional indications for DA-1241, their oral GPR119 agonist. This partnership will utilize Syntekabio's DeepMatcher AI platform to identify new therapeutic targets, building on positive Phase 2a study results showing DA-1241's safety and efficacy. The collaboration aims to enhance the therapeutic potential of DA-1241 for treating conditions associated with metabolic dysfunction. Initial insights from this collaboration are anticipated later this year.
Read more →MTVAMetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research...
MetaVia Inc. has announced a collaboration with Syntekabio to explore additional indications for DA-1241, a novel GPR119 agonist. This partnership will utilize Syntekabio's AI-driven DeepMatcher platform to identify new therapeutic targets. The collaboration follows positive results from a Phase 2a study, which demonstrated DA-1241's safety and efficacy in patients with metabolic dysfunction.
Read more →MTVA▲ +8.2%on this news
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose Top-Line Data Expected in the Fourth Quarter of
MetaVia Inc. has successfully dosed the first patient in the 48 mg multiple ascending dose cohort of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog for obesity treatment. Top-line data from this trial is expected in the fourth quarter of 2025. Initial results from earlier trials show DA-1726's potential for significant weight loss, improved glucose control, and favorable safety profiles compared to existing therapies. The trial's design allows for the assessment of safety, tolerability, and other metabolic parameters, which are crucial for the drug's development.
Read more →MTVA▲ +8.2%on this news
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the...
MetaVia Inc. has initiated dosing of the first patient in the 48 mg cohort of its Phase 1 clinical trial for DA-1726, aimed at treating obesity. This trial will explore the maximum tolerated dose and build on previous positive results from a 32 mg dose. Top-line data is anticipated in Q4 2025, with DA-1726 showing promising weight loss and safety profiles.
Read more →MTVAMetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA
MetaVia Inc. has presented pre-clinical data on DA-1241, a GPR119 agonist, showing its additive hepatoprotective effects when combined with Efruxifermin at the American Diabetes Association's Scientific Sessions. The combination therapy helped reduce liver fat, inflammation, and fibrosis in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). Notably, 94% of treated mice experienced significant improvements in liver health metrics compared to monotherapy. These findings support the potential of DA-1241 as a key component in addressing MASH through combination therapy.
Read more →MTVAMetaVia Announces Poster Presentation on DA-1241 at the ADA
MetaVia Inc. has announced that an abstract on DA-1241, a novel GPR119 agonist, will be presented at the American Diabetes Association's 85th Scientific Sessions. The presentation is scheduled for June 22, 2025, and focuses on DA-1241’s hepatoprotective effects in a mouse model. This therapy is being developed to target Metabolic Dysfunction-Associated Steatohepatitis (MASH) and has shown promising results in pre-clinical studies and early phase clinical trials.
Read more →MTVA▲ +26.8%on this news
December 2023 NASDAQ: NRBO 1 May 2025 MetaVia Inc. NASDAQ: MTVA 2 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199
MetaVia Inc. shared promising data regarding its drug candidates, particularly DA-1726 and DA-1241. DA-1726 demonstrated substantial weight loss results, improved tolerability, and favorable safety profiles in clinical studies. Additionally, DA-1241 met primary endpoints in a Phase 2a trial, indicating significant effects on hepatic health. The company continues to seek partnerships to advance its promising pipeline targeting obesity and related conditions.
Read more →MTVAMetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Pote
MetaVia Inc. reported positive first quarter 2025 financial results and provided updates on its clinical trials. The Phase 1 MAD trial results for DA-1726 demonstrated promising weight loss and glucose control, with plans for additional cohorts to determine the maximum tolerated dose. Financially, the company successfully raised $10 million, extending its funding through 2026. Additionally, promising Phase 2a trial results for DA-1241 indicate its potential benefits for liver health and glycemic control.
Read more →MTVAMetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a...
MetaVia Inc. announced a private placement expected to raise approximately $10 million to support its clinical development efforts, particularly for DA-1726, aimed at treating obesity. The offering includes common stock and pre-funded warrants, priced at-the-market under Nasdaq rules. The closing is anticipated around May 12, 2025, subject to customary conditions.
Read more →MTVAMetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
MetaVia Inc. has announced a successful private placement expected to generate approximately $10 million in gross proceeds. The funds will primarily be used for working capital and to further develop DA-1726, which is aimed at treating obesity. The offering, priced at-the-market under Nasdaq rules, includes the sale of common stock and pre-funded warrants. Closing is anticipated to occur on or about May 12, 2025, pending customary closing conditions.
Read more →MTVA▼ -8%on this newsshared move
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from...
MetaVia Inc. announced positive results from its Phase 2a trial of DA-1241, a GPR119 agonist, showing significant hepatoprotective and glucose-regulating effects in patients with presumed MASH. The treatment led to a notable reduction in plasma ALT levels and improvements in liver fat content and inflammatory biomarkers. The findings will be presented at the EASL Congress 2025.
Read more →MTVA▼ -8%on this newsshared move
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 DA-1241 Significantly Decreased Plasma ALT
MetaVia Inc. announced promising results from its Phase 2a clinical trial of DA-1241, an oral GPR119 agonist, at the EASL Congress 2025. The trial demonstrated that DA-1241 significantly decreased plasma ALT levels and improved systemic inflammatory and fibrosis biomarkers in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the treatment provided glucose-regulating effects, enhancing glycemic control in participants. With a favorable safety profile observed, the company aims to further develop DA-1241 as either monotherapy or in combination therapies for MASH and related metabolic diseases.
Read more →MTVA▲ +8.4%on this news
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
MetaVia Inc. announced that an abstract detailing data from its Phase 2a clinical trial of DA-1241 was accepted as a late-breaking poster presentation at the EASL Congress 2025. DA-1241 is a GPR119 agonist designed to address metabolic dysfunction-associated steatohepatitis (MASH). The results showcased the compound's potential in regulating glucose metabolism and demonstrating hepatoprotective properties. The presentation is scheduled for May 7, 2025, enhancing the visibility of MetaVia's work in transforming treatments for cardiometabolic diseases.
Read more →MTVAMetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the ...
MetaVia Inc. reported positive results from the Phase 1 MAD study of DA-1726, a dual receptor agonist for obesity. The study showed a significant dose-dependent reduction in body weight and BMI, with no adverse cardiovascular effects noted. The company plans to add additional cohorts to assess maximum tolerated doses and further evaluate the drug's potential.
Read more →MTVAMetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 , a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity , Further Demonstrating Its Best-In-C
MetaVia Inc. has reported additional positive results from the MAD Part 2 of its Phase 1 clinical trial for DA-1726, a dual receptor agonist for treating obesity. The study demonstrated a clear dose-dependent reduction in body weight and significant differences in BMI compared to placebo. Importantly, DA-1726 did not produce any adverse cardiovascular effects at doses up to 32 mg. Management emphasized the promising safety profile and potential of DA-1726 as an effective treatment option for obesity.
Read more →MTVA▼ -56%on this news
December 2023 NASDAQ: NRBO 1 April 2025 MetaVia Inc. NASDAQ: MTVA 2 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1
MetaVia Inc. (NASDAQ: MTVA) has reported encouraging findings from its pipeline candidate DA-1726, targeting obesity and MASH. In a recent study, DA-1726 demonstrated significant weight loss and noteworthy reductions in fasted glucose levels after four weeks of treatment. The results suggest potential best-in-class efficacy and safety, positioning DA-1726 favorably against other obesity treatments. The company plans to further explore this drug's capabilities in clinical trials and is seeking partnership opportunities for development and commercialization.
Read more →MTVA▼ -56%on this news
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated...
MetaVia Inc. announced positive results from its Phase 1 MAD trial of DA-1726, a dual receptor agonist for obesity. The trial showed a maximum weight loss of 6.3% and excellent safety with no serious adverse events. Early satiety was reported in most patients, suggesting potential efficacy. The company plans to expand the study to further explore DA-1726's tolerability and effectiveness.
Read more →MTVA▼ -56%on this news
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Poten
MetaVia Inc. has announced positive top-line data from the Phase 1 multiple ascending dose trial of its dual receptor agonist DA-1726, aimed at treating obesity. The trial results indicated promising safety and efficacy, showing significant weight loss, with a maximum reduction of 6.3% at a 32 mg dose without titration. The results also suggested DA-1726 may offer advantages in glucose control compared to other treatments. Furthermore, the company plans to add more cohorts and explore the drug's potential on patients who previously dropped out of treatment with Wegovy.
Read more →MTVATop-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating
MetaVia Inc. has announced positive top-line results from the Phase 2a trial of DA-1241, showing reductions in alanine transaminase levels and improvements in hemoglobin A1C. The company anticipates releasing top-line data from the MAD Part 2 of the Phase 1 trial of DA-1726 in April 2025, which targets obesity treatment. With $16 million in cash, MetaVia is well-positioned to continue its clinical development, aiming for an early proof-of-concept study for DA-1726 by late 2025. Both candidates show promise in their respective therapeutic areas focused on cardiometabolic diseases.
Read more →MTVAMetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
MetaVia Inc. reported its financial results for the year ended December 31, 2024, highlighting advancements in its clinical trials for DA-1726 and DA-1241. The Phase 2a trial of DA-1241 showed promising results in treating MASH, achieving primary and secondary endpoints related to liver health. Despite a significant increase in operating losses and high R&D expenditures, the company maintains a strong cash position of $16 million to support ongoing development efforts. Future clinical milestones include anticipated top-line data for DA-1726 in April 2025.
Read more →MTVAMetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
MetaVia Inc. is holding an Advisory Committee meeting at the 9th Annual MASH-TAG 2025 Conference to discuss positive results from its Phase 2a clinical trial of DA-1241. This novel GPR119 agonist showed promising outcomes for patients with metabolic dysfunction-associated steatohepatitis. The conference, taking place in Park City, Utah, allows MetaVia's management to engage with attendees about the trial results. Additionally, the company is developing another candidate, DA-1726, which aims to treat obesity by targeting specific gut hormone receptors.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 Jan 2025 NASDAQ: MTVA DA-1241 Phase 2a Topline Data MASH-TAG 2025 2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Secur
MTVA's DA-1241 Phase 2a trial has reported promising topline data showing significant reductions in ALT, HbA1C, CAP, and FAST scores compared to placebo. The study included various dosing regimens and demonstrated a strong safety profile in patients with presumed non-alcoholic steatohepatitis (NASH). Importantly, the company is financially well-positioned with approximately $21.7 million in cash, which supports its operations and future studies. However, the prognosis relies on various uncertain factors as highlighted in the forward-looking statements.
Read more →MTVAMetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MetaVia Inc. will participate as a Sponsor and Exhibitor at the 9th Annual MASH-TAG 2025 Conference following positive results from its Phase 2a clinical trial of DA-1241. The trial assessed this novel GPR119 agonist in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Scheduled for January 9-11 in Park City, Utah, the conference offers a platform for MetaVia's management and clinical team to discuss their findings. DA-1241 has exhibited beneficial effects on liver health, glucose metabolism, and body weight management.
Read more →MTVA▼ -17.7%on this newsshared move
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering Effect Patients Treate
MetaVia Inc. recently announced positive results from its Phase 2a clinical trial of DA-1241 for patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial, which examined DA-1241 both as a standalone treatment and in combination with sitagliptin, showed a statistically significant reduction in alanine transaminase (ALT) levels at various points over the 16-week period. Notable secondary endpoints also indicated improvements in other liver function markers and HbA1c levels. The results support DA-1241's continued development as a promising treatment option for MASH.
Read more →MTVAMetaVia to Present at the Emerging Growth Conference in December
MetaVia Inc. will showcase its latest developments at the Emerging Growth Conference on December 4, 2024. CEO Hyung Heon Kim and CFO Marshall H. Woodworth will outline the company's progress in treating cardiometabolic diseases, including its promising candidates, DA-1726 and DA-1241. Both candidates demonstrate significant potential for understanding obesity and liver-related conditions. Attendees will have the opportunity to ask questions during and after the presentation.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 November 2024 NASDAQ: MTVA MetaVia Inc. 2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Ac
MetaVia Inc. is gearing up for multiple near-term clinical milestones in its drug development pipeline. The company is actively advancing its DA-1241 and DA-1726 programs, which focus on treating conditions like obesity and metabolic-associated steatotic liver disease (MASH). Results from ongoing trials are expected to yield data that could significantly enhance shareholder value. With solid financial backing and promising safety profiles, the firm is positioning itself for future growth pending regulatory approvals.
Read more →MTVANeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases New Nasdaq Ticker Symbol will be
NeuroBo Pharmaceuticals has announced a strategic realignment, changing its corporate name to MetaVia, effective November 29, 2024. The company will also adopt a new stock ticker symbol, MTVA, as it refocuses on developing therapies for cardiometabolic diseases. Notably, MetaVia expects to report data from its Phase 2a clinical trial of DA-1241 and top-line data from the Phase 1 trial of DA-1726 in the coming months. Both drug candidates target significant metabolic diseases, with DA-1726 positioned as a potentially superior obesity treatment.
Read more →MTVANeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of
NeuroBo Pharmaceuticals reported its third-quarter 2024 financial results, highlighting positive top-line data from the Phase 1 clinical trial of DA-1726 for obesity. The trial demonstrated a favorable safety profile, which enables further investigations into optimal dosing. Cash reserves of $21.7 million are expected to sustain operations through to Q3 2025. Additionally, the company anticipates key clinical milestones, including results from DA-1241's Phase 2a trial by December 2024 and continuing development collaborations.
Read more →MTVANeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH Topline Data Readout From Part 1 and Part 2 Expected in December 2024
NeuroBo Pharmaceuticals has successfully completed the last patient last visit in its Phase 2a clinical trial for DA-1241, a GPR119 agonist aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). The trial consists of two parts, with topline data readout anticipated in December 2024. Preliminary results from earlier studies have indicated that DA-1241 might have beneficial effects on liver inflammation and metabolic health. The trial's progress represents a significant step in the development of potential therapies for patients suffering from MASH.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 October 2024 NeuroBo Pharmaceuticals, Inc. 2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform
NeuroBo Pharmaceuticals is focusing on advancing its drug candidates DA-1241 and DA-1726 through critical clinical trials aimed at treating obesity and non-alcoholic steatohepatitis (MASH). The company anticipates several key milestones in 2024 and 2025, including Phase 2 and Phase 1 trial results, which are critical for assessing the drug's efficacy and safety. The financial stability, provided by a cash reserve of $27.9 million and support from a strategic partner, positions NeuroBo favorably as it seeks to enhance shareholder value through successful clinical outcomes. However, the success of these trials is not assured, introducing risks related to regulatory approval.
Read more →MTVANeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity Data Revealed Favorable Safety, Tolerability and Dose-Linear Phar
NeuroBo Pharmaceuticals announced positive top-line data from the SAF Part 1 of its Phase 1 clinical trial for DA-1726, an obesity treatment. The data indicated favorable safety, tolerability, and a dose-linear pharmacokinetic profile from the single ascending dose trial involving 45 participants. Building on these results, NeuroBo is proceeding with additional cohorts and anticipates reporting data from the multiple ascending dose (MAD) Part 2 in early 2025. The company is optimistic about DA-1726's potential as a leading obesity drug due to its balanced mechanism of action.
Read more →MTVANeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggre
NeuroBo Pharmaceuticals reported its financial results for Q2 2024, highlighting a successful financing of up to $70 million with $20 million upfront. The company anticipates significant progress in its clinical trials for DA-1726, a new treatment for obesity, supported by positive preclinical data. However, there was a substantial increase in net losses and R&D expenses compared to the previous year, indicating challenges in managing operational costs as they pursue developmental milestones.
Read more →MTVANeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity No Significant Issues Encountered During the Single Ascending Dose (SAD) Study,
NeuroBo Pharmaceuticals has completed the enrollment for the SAD Part 1 of its Phase 1 clinical trial of DA-1726, aimed at treating obesity. The trial, involving 45 participants, proceeded without significant issues, allowing for an earlier initiation of the MAD Part 2 study. Top-line data from the SAD trial is expected in Q3 2024, with further evaluations planned in subsequent phases. Meanwhile, pre-clinical data indicate the potential advantages of DA-1726 over existing obesity treatments.
Read more →MTVANeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity Collaboration to Leverage Immu
NeuroBo Pharmaceuticals announced a joint research agreement with Dong-A ST and ImmunoForge to develop DA-1726, a long-acting obesity treatment. The collaboration aims to leverage ImmunoForge's ELP platform to enhance the drug's formulation for once-monthly administration. DA-1726, currently in Phase 1 studies, is a dual agonist targeting GLP-1 and GCGR receptors, showing promising results in pre-clinical trials. The agreement is a strategic step toward potentially revolutionizing obesity treatments and improving patient compliance.
Read more →MTVANeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
NeuroBo Pharmaceuticals has signed an exclusive license agreement with MThera Pharma for the development of NB-01, targeting painful diabetic neuropathy. This agreement gives MThera rights to conduct further research, including a potential Phase 3 clinical trial in the U.S. and South Korea. NeuroBo's CEO emphasized the significance of this milestone, as it allows the company to focus on its ongoing clinical programs while partnering with a firm experienced in manufacturing and clinical development of botanical drugs.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 July 2024 NeuroBo Pharmaceuticals, Inc. 2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Ac
NeuroBo Pharmaceuticals is focusing on advancing its clinical pipeline, particularly with DA-1241 and DA-1726, which are in various phases of trials aimed at treating obesity and MASH. Both drugs are expected to reach key clinical milestones in 2024 and 2025 that could positively impact shareholder value. The company reported a strong cash position, which could support ongoing research and development. However, the success of these trials hinges on regulatory approvals and clinical outcomes, which are not assured.
Read more →MTVANeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $20 million upfront with up to an additional $50 mill
NeuroBo Pharmaceuticals has announced the successful closing of a private placement and a registered direct offering totaling up to $70 million. This includes an upfront $20 million and an additional $50 million potentially from Series Warrants tied to clinical milestones. The capital raised will support the ongoing clinical development of DA-1726, a treatment for obesity. The offerings were conducted under Nasdaq rules, with H.C. Wainwright & Co. acting as the placement agent.
Read more →MTVANeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $20 million upfront with up to an additional $50 million of aggregat
NeuroBo Pharmaceuticals has announced a financing arrangement through a concurrent private placement and registered direct offering, potentially raising up to $70 million. The initial $20 million is secured from a private placement, with the possibility of an additional $50 million based on the exercise of Series Warrants linked to clinical milestones. The proceeds are earmarked for working capital and advancing the clinical development of DA-1726, aiming to improve treatments for obesity. The offerings are subject to completion of customary conditions and regulatory approvals.
Read more →MTVANeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models DA-1726 Also Exhibited Superior Glucose Lo
NeuroBo Pharmaceuticals announced that its candidate DA-1726 has demonstrated superior efficacy in weight loss and lipid lowering when compared to survodutide, according to new pre-clinical data presented at the ADA 84th Scientific Sessions. The dual agonist of GLP-1 and glucagon receptors exhibited not only better weight loss but also retention of lean body mass and improved cholesterol levels. The ongoing Phase 1 trial is progressing well, with further data expected later this year. The findings suggest DA-1726 may position itself as a leading treatment for obesity and related metabolic disorders.
Read more →MTVANeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone Data Will be Pre
NeuroBo Pharmaceuticals has announced promising pre-clinical results for its DA-1241 drug in combination with semaglutide, showing improvements in liver fibrosis and overall metabolic health in models of metabolic dysfunction-associated steatohepatitis (MASH). The findings, which will be presented at the EASL Congress 2024, demonstrate additive hepatoprotective effects of the combination therapy compared to each treatment alone. The company is also advancing its Phase 2a clinical trial of DA-1241, seeking to further explore its therapeutic implications for MASH. The unique mechanism of DA-1241's action may provide a safe and effective treatment for liver inflammation and fibrosis.
Read more →MTVANeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Lin
NeuroBo Pharmaceuticals announced its first quarter 2024 financial results and a corporate update, highlighting the dosing of the first patient in the Phase 1 clinical trial of DA-1726 for obesity. The company expects to report top-line data from this trial in the third quarter of 2024. Additionally, it has fully enrolled Part 1 of the Phase 2a trial for DA-1241, targeting metabolic dysfunction-associated steatohepatitis (MASH), with results anticipated in the fourth quarter of 2024. However, the company's cash reserves have decreased, raising concerns about funding for ongoing trials.
Read more →MTVANeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
NeuroBo Pharmaceuticals has announced the acceptance of poster presentations for its cardiometabolic assets DA-1241 and DA-1726 at the EASL Congress 2024 and ADA 84th Scientific Sessions in June. The company reports advancements in clinical trials, including the completion of enrollment for the Phase 2a trial of DA-1241 and the dosing of the first patient in the Phase 1 trial of DA-1726. Both compounds target obesity and metabolic disorders. NEuroBo is optimistic about the potential impact and outcomes of these assets based on preclinical data.
Read more →MTVANeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascen
NeuroBo Pharmaceuticals has successfully dosed the first patient in the Phase 1 clinical trial of DA-1726, a novel treatment for obesity. This advancement marks a significant step in testing this dual agonist in humans, with safety and tolerability being the primary focus. The trial is expected to report top-line data by the third quarter of 2024, indicating a rapid progression in its timelines. NeuroBo aims to demonstrate DA-1726's effectiveness compared to existing obesity treatments.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 April 2024 NeuroBo Pharmaceuticals, Inc. 2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform A
NeuroBo Pharmaceuticals is advancing its drug candidates DA-1241 and DA-1726 through significant clinical milestones, targeting obesity and metabolic disorders. DA-1241 is currently in a Phase 2a trial for presumed non-alcoholic steatohepatitis (MASH), while DA-1726 is set to enter its Phase 1 Part 3 trial. The company's strong cash position, totaling $22.4 million, enables continued investment in these promising developments. However, the success of these clinical trials remains uncertain and subject to regulatory scrutiny.
Read more →MTVANeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH Full Data Readout Expected in the Second Half of 2024
NeuroBo Pharmaceuticals has successfully completed enrollment for Part 1 of its Phase 2a clinical trial evaluating DA-1241, a GPR119 agonist, for treating metabolic dysfunction-associated steatohepatitis (MASH). A total of 49 patients were randomized in three treatment groups, with the study designed as a double-blind, placebo-controlled trial. The company anticipates that Part 2 will provide additional insights into DA-1241's efficacy, particularly when combined with sitagliptin. Full trial data is expected to be reported in the second half of 2024, marking a significant step in NeuroBo's clinical development efforts.
Read more →MTVANeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1
NeuroBo Pharmaceuticals reported its year-end 2023 financial results and a corporate update, highlighting significant progress in clinical trials. The company has received Institutional Review Board approval to initiate a Phase 1 trial for DA-1726, targeting obesity, and has received recommendations to continue the Phase 2a trial of DA-1241 for MASH without modifications based on safety reviews. With a cash reserve of $22.4 million, NeuroBo anticipates having sufficient funds to support its operations into the fourth quarter of 2024.
Read more →MTVANeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH Blinded Safety Review Completed for the First 6 Months of the Ph
NeuroBo Pharmaceuticals has received approval from the Safety Review Committee (SRC) to continue with its Phase 2a clinical trial evaluating DA-1241 for metabolic dysfunction-associated steatohepatitis (MASH). The SRC's recommendation comes after a blinded safety review indicated no significant adverse safety trends in the first six months of the trial. The trial is exploring the efficacy and safety of DA-1241, with comprehensive data readout expected in the latter half of 2024. DA-1241 has shown promise in preclinical and early clinical studies for improving liver health and glucose control.
Read more →MTVANeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer CAMBRIDGE
NeuroBo Pharmaceuticals has appointed Marshall Woodworth as the Chief Financial Officer effective March 1, 2024, after he served as Acting CFO since late October 2023. Woodworth brings extensive experience from previous CFO roles in various biotech firms. He is optimistic about advancing NeuroBo's two key assets, DA-1241 and DA-1726, with upcoming clinical trials and notable FDA approval progress. The company focuses on tackling cardiometabolic diseases, and Woodworth's leadership is expected to drive successful clinical outcomes.
Read more →MTVANeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity First Patient Expected to be Randomized in the Second Quarter of 2024
NeuroBo Pharmaceuticals has announced that it has received the first site Institutional Review Board (IRB) approval for its Phase 1 clinical trial of DA-1726, aimed at treating obesity. The trial will evaluate the safety and efficacy of the drug, with the first patient expected to be randomized in Q2 2024. DA-1726 is a dual agonist targeting GLP-1 and glucagon receptors and has shown promising weight loss results in preclinical models. The study aims to enroll approximately 81 participants overall and will monitor various health metrics throughout the trial.
Read more →MTVADecember 2023 NASDAQ: NRBO 1 February 2024 NeuroBo Pharmaceuticals, Inc. 2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Refor
NeuroBo Pharmaceuticals, Inc. is targeting to increase shareholder value through multiple near-term milestones associated with its DA-1241 and DA-1726 clinical trials. The company has outlined various key milestones, including upcoming submission protocols and patient recruitment timelines for the trials. DA-1241 is being developed for the treatment of MASH and type 2 diabetes, while DA-1726 aims to address obesity with promising outcomes in animal studies. With significant cash reserves as of Q3 2023, NeuroBo is positioned to advance these important therapeutic candidates.
Read more →MTVANeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy )
NeuroBo Pharmaceuticals has received FDA clearance for its Investigational New Drug application to initiate a Phase 1 clinical trial of DA-1726, a novel treatment aimed at obesity. Preclinical studies indicate that DA-1726 provides superior weight loss compared to semaglutide while allowing higher food intake, presenting a potentially better tolerability profile. The trial is scheduled to begin in the first half of 2024, with results expected by the first half of 2025.
Read more →MTVANeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH Ful
NeuroBo Pharmaceuticals has announced positive pre-clinical safety data for its drug DA-1241, a GPR119 agonist, in combination with sitagliptin for treating metabolic dysfunction-associated steatohepatitis (MASH). The company has opened enrollment for Part 2 of its Phase 2a clinical trial after satisfying FDA protocol commitments. The pre-clinical results showed that the combination therapy was well tolerated in animal studies, and NeuroBo expects to report full data from the trial in the second half of 2024.
Read more →MTVANeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
NeuroBo Pharmaceuticals has announced that it is now compliant with Nasdaq's minimum bid price requirement, formally receiving notification on January 8, 2024. This compliance allows the company to continue its listing on the Nasdaq Capital Market, which is a significant aspect of maintaining investor confidence. NeuroBo is advancing its clinical-stage products, aiming to transform therapies for cardiometabolic diseases, with two main candidates: DA-1241 and DA-1726. Early studies on these drug candidates have shown promising results in treating conditions such as Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus.
Read more →MTVANeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals has submitted an Investigational New Drug application to the FDA for its Phase 1 clinical trial of DA-1726, aimed at treating obesity. This dual agonist targeting GLP-1 and glucagon receptors has shown promising preclinical results, including effective weight loss compared to current treatments. The clinical trial will assess safety, tolerability, and pharmacokinetics and is expected to begin in the first half of 2024. Positive preclinical outcomes position DA-1726 as a potentially beneficial option in the obesity market.
Read more →MTVANeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split Commencement of Trading on Split-Adjusted Basis on
NeuroBo Pharmaceuticals announced a 1-for-8 reverse stock split set to take effect on December 21, 2023. This decision follows approval from shareholders during the annual meeting in June, aimed at complying with Nasdaq's continued listing requirements. The move reduces the number of outstanding shares from approximately 38.8 million to 4.85 million, which may enhance trading dynamics but raises concerns regarding liquidity and investor confidence. The company's common stock will continue to trade under the symbol 'NRBO' following the split.
Read more →MTVANASDAQ: NRBO December 2023 NeuroBo Pharmaceuticals, Inc. 2 This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements i
NeuroBo Pharmaceuticals is exploring strategic opportunities to out-license legacy assets while focusing on obesity and metabolic conditions with its drug pipeline. The company reports a solid cash balance of $25.8 million as of September 2023, which will support ongoing studies, including a Phase 2a trial for DA-1241 targeting liver conditions and another for DA-1726, a dual agonist for obesity. Recent data has shown promising weight loss results for DA-1726 in animal models, performing better than approved products like Semaglutide. Plans for an Investigational New Drug application for DA-1726 are set for December 2023.
Read more →MTVANeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update DA-1726 Phase 1 IND Filing Expected by Year End 2023 Board Strengthened with Recent Appointment of Industry Veteran, Jame
NeuroBo Pharmaceuticals reported its third quarter 2023 financial results, highlighting advancements in its clinical programs. The company is moving forward with the Phase 2a clinical trial of DA-1241 for NASH and plans to file for IND approval for DA-1726 by year-end 2023. NeuroBo has approximately $25.8 million in cash to support operations through multiple upcoming milestones. Furthermore, the recently appointed board member, Dr. James P. Tursi, is expected to bring valuable industry experience to the team.
Read more →MTVANeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi
NeuroBo Pharmaceuticals has appointed James P. Tursi, M.D., to its Board of Directors, effective November 1, 2023. Dr. Tursi brings nearly 20 years of experience in the pharmaceutical industry and will also partake in the Board's Nominating and Corporate Governance Committee. With multiple clinical development milestones on the horizon for NeuroBo's cardiometabolic drug candidates, including DA-1241 and DA-1726, the company anticipates advancements in addressing critical health issues such as NASH and obesity.
Read more →MTVANeuroBo Pharmaceuticals, Inc. NASDAQ: NRBO September 2023 0.66” 0.66” 2 Forward Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litig
NeuroBo Pharmaceuticals has outlined its strategic approach to addressing the growing obesity crisis and non-alcoholic steatohepatitis (NASH) with a pipeline of next-generation therapeutics. The company is poised to initiate multiple development programs and has financial backing of $28.9 million as of June 30, 2023. Notably, the market for obesity is expected to reach $54 billion by 2030, indicating significant growth potential. NeuroBo's development efforts include IND submissions for drugs targeting these conditions, aiming to create shareholder value through timely milestones.
Read more →MTVANeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024 Full Data Readout Ex
NeuroBo Pharmaceuticals announced the dosing of its first patient in a Phase 2a clinical trial for DA-1241, aimed at treating nonalcoholic steatohepatitis (NASH). The trial features a two-part design, allowing for an optional interim analysis in 2024 and a full data readout expected in the latter half of 2024. DA-1241, a G-Protein-Coupled Receptor 119 agonist, has shown efficacy in reducing liver inflammation and promoting glucose control in preclinical studies. This trial marks a significant step in the development of treatment options for NASH, a condition currently lacking approved therapies.
Read more →MTVANeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023 Cash and Cash Equivalents of $28.7
NeuroBo Pharmaceuticals has reported its Q2 2023 financial results, revealing a net loss of $3.3 million. The company anticipates dosing its first patient in the Phase 2a trial for DA-1241, targeting non-alcoholic steatohepatitis (NASH) this September. Additionally, promising preclinical data for DA-1726 indicates potential for effective obesity treatment. With cash reserves of $28.7 million, NeuroBo looks to fund ongoing and future clinical milestones as it explores out-licensing opportunities for its legacy programs.
Read more →MTVANeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of
NeuroBo Pharmaceuticals has received its first Institutional Review Board (IRB) approval for a clinical trial evaluating DA-1241 for the treatment of nonalcoholic steatohepatitis (NASH). The Phase 2a trial is set to begin dosing patients in September 2023 and includes a two-part design to assess efficacy and safety. DA-1241, a G-Protein-Coupled Receptor 119 (GPR119) agonist, has shown beneficial effects in preclinical models, with the potential to improve liver health and glucose metabolism.
Read more →MTVANeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models Preclinical Data Also Show DA-1726 Effectiv
NeuroBo Pharmaceuticals announced promising preclinical data for DA-1726, a dual agonist targeting GLP1R and GCGR, showing superior weight loss efficacy compared to Semaglutide and Tirzepatide. Presented at the American Diabetes Association's 83rd Scientific Sessions, DA-1726 demonstrated significant reductions in body weight in preclinical models, along with improvements in metabolic parameters such as plasma glucose. The company plans to advance DA-1726 through the IND process and aims to initiate a Phase 1a safety study in early 2024.
Read more →MTVANeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83 rd Scientific Sessions BOS
NeuroBo Pharmaceuticals announced that its novel GLP1R and GCGR dual agonist, DA-1726, has been accepted for two poster presentations and one ePoster discussion at the American Diabetes Association's 83rd Scientific Sessions. The event will take place from June 23-26, 2023, in San Diego. Interim CEO Joe Hooker indicated that the recognition at such a significant meeting underscores the strength of DA-1726's preclinical data. The company plans to initiate a phase 1a safety study by the first half of 2024, pending FDA acceptance.
Read more →MTVANeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors BOSTON
NeuroBo Pharmaceuticals, Inc. has appointed Mark A. Glickman to its Board of Directors, effective May 11, 2023. Glickman brings over 30 years of experience in the pharmaceutical industry, having held various senior leadership roles. His expertise is expected to support the advancement of NeuroBo's cardiometabolic assets, DA-1241 and DA-1726, as the company aims to address significant health issues like NASH and obesity. The company plans to initiate a two-part Phase 2a clinical trial and an IND application process for these promising treatments in the coming months.
Read more →MTVANeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023 BOSTON
NeuroBo Pharmaceuticals has received FDA clearance for its IND application for DA-1241, which is set to begin Phase 2a clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) in Q3 2023. The drug candidate demonstrated well-tolerated outcomes in earlier studies and showed promise in reducing inflammation and fibrosis associated with NASH. The two-part, randomized trial design includes up to 55 subjects for efficacy evaluation and anticipates interim results by early 2024. This development comes alongside the company’s broader focus on cardiometabolic diseases, including another asset, DA-1726, for obesity treatment.
Read more →MTVANeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of
NeuroBo Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application to the FDA for its Phase 2a clinical trial of DA-1241, aimed at treating nonalcoholic steatohepatitis (NASH). This follows promising preclinical results demonstrating the drug's ability to reduce hepatic steatosis and improve metabolic parameters. If the IND receives regulatory approval, the company plans to start patient enrollment in the third quarter of 2023. NeuroBo also aims to advance another asset, DA-1726, through the IND process this year.
Read more →MTVANeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results Company Pipeline to Focus on Cardiometabolic Disease Cash and Cash Equivalents to Fund the Company into 2024 BOSTON
NeuroBo Pharmaceuticals reported its financial results for 2022, highlighting a strategic shift towards cardiometabolic diseases with the acquisition of new assets. The company has secured funding and has cash reserves to operate into 2024, planning to initiate phase 2a studies for DA-1241 in NASH later this year. However, the financial report showed a net loss that increased in comparison to the previous year, emphasizing the challenges ahead as the company focuses on successful product development and commercialization.
Read more →MTVANeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience BOSTO
NeuroBo Pharmaceuticals has appointed Joseph Hooker as Interim Chief Executive Officer and President following the retirement of Gil Price. Hooker's extensive experience in the pharmaceutical industry is expected to aid NeuroBo as it advances its newly acquired assets, DA-1241 and DA-1726, into clinical development stages. The company is also focused on securing a permanent CEO while enhancing its strategic priorities and financial position. NeuroBo aims to exploit opportunities in the NASH and obesity markets, with significant potential for future growth.
Read more →MTVANEUROBO ANNOUNCES PRICING OF $30
NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT BOSTON, MA, November 4, 2022 - NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) (the "Company" or "NeuroBo") today announced the pricing of an underwritten public offering of unit
Read more →MTVANeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria BOSTON, MA
NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria BOSTON, MA, September 29, 2022 - NeuroBo Pharmaceuticals, Inc. ("NeuroBo") (Nasdaq: NRBO) today announced that on September 27, 2022, NeuroBo received formal notice from the Listing Qualificat
Read more →MTVANeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies Exclusive License Agreement to Develop and Commercialize Phase
NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies BOSTON, MA, and SEOUL, SOUTH KOREA, September 15, 2022 - NeuroBo Pharmaceuticals, Inc. ("NeuroBo") (Nasdaq: NRBO), and
Read more →MTVANeuroBo Pharmaceuticals Announces Reverse Stock Split BOSTON
NeuroBo Pharmaceuticals Announces Reverse Stock Split BOSTON, September 12, 2022 /PRNEWSWIRE/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company, announced today a 1-for-30 reverse split of its Common Stock, par va
Read more →MTVANeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results BOSTON
NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results BOSTON, April 1, 2022 - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced financial results for the year ended December 31, 2021. Management Commentary "Since I
Read more →MTVANeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors BOSTON
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors BOSTON, January 28, 2022 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directo
Read more →MTVANeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results BOSTON
NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results BOSTON, November 15, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neur
Read more →MTVANeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer Industry Leader Brings More than 30 Years of Pharmaceutical, CRO and Entrepreneurial Experience BOSTON
NeuroBo Pharmaceuticals Appoints Gil Price, and Chief Executive Officer Industry Leader Brings More than 30 Years of Pharmaceutical, CRO and Entrepreneurial Experience November 4, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company foc
Read more →MTVANEUROBO PHARMACEUTICALS ANNOUNCES $14
PHARMACEUTICALS ANNOUNCES $14 MILLION REGISTERED DIRECT OFFERING 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic an
Read more →MTVANeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results BOSTON
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results BOSTON, August 16, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuro
Read more →MTVANeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors Experienced Leaders Bring More Than 30 Years of Industry Expertise BOSTON
NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors Experienced Leaders Bring More Than 30 Years of Industry Expertise BOSTON, July 12, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnolo
Read more →MTVANeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results BOSTON
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results BOSTON, May 17, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropath
Read more →MTVANeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflect
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 BOSTON, April 15, 2020 -- NeuroBo Pharm
Read more →MTVANeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene Gemcabene to be Studied as a Stand-alone Treatment for COVID-19 and in Combination with Lead Asset, ANA001 BOSTON
NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene Gemcabene to be Studied as a Stand-alone Treatment for COVID-19 and in Combination with Lead Asset, ANA001 BOSTON, March 24, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a
Read more →MTVACompany Presentation Confidential March 2021 2 Disclaimers This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Secu
Company Presentation Confidential March 2021 2 Disclaimers This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for stateme
Read more →MTVANeuroBo Pharmaceuticals Announces $10.0 Million Private Placement BOSTON
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement BOSTON, January 19, 2021 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has entered into securities purchase agreements with certain institutional
Read more →MTVACompany Presentation
This is a unique opportunity in biotech/pharma and expected to be particularly valuable in priority jurisdictions. 26 ANA-001 and COVID-19 Clinical COVID-19: Timeline Slide for ANA-001 Commercial Development PH 2 Data (Early Sept) 1st EUA Request (Sept) EoP2 Meeting (Sept-Oct) 2n
Read more →MTVANeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program Transformative Acquisition Deepens Pipeline with In-Process Phase 2/3 Clinical Study of Proprietary Oral Formulation of
NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program Transformative Acquisition Deepens Pipeline with In-Process Phase 2/3 Clinical Study of Proprietary Oral Formulation of Niclosamide for the Treatment of COVID-19 Development Time
Read more →MTVANeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors Industry Veteran Brings More Than 20 Years of Corporate Leadership and Investment Banking Expertise BOSTON
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors Industry Veteran Brings More Than 20 Years of Corporate Leadership and Investment Banking Expertise BOSTON, September 2, 2020 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechn
Read more →MTVANeuroBo Pharmaceuticals Announces Continuation of Partial Clinical Hold of Gemcabene BOSTON
NeuroBo Pharmaceuticals Announces Continuation of Partial Clinical Hold of Gemcabene BOSTON, May 26, 2020 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies fo
Read more →MTVANeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering BOSTON
NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering BOSTON, April 14, 2020 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodeg
Read more →MTVANeuroBo Pharmaceuticals Reports Year End 2019 Financial Results and Provides Corporate Strategic Update BOSTON
NeuroBo Pharmaceuticals Reports Year End 2019 Financial Results and Provides Corporate Strategic Update BOSTON, March 30, 2020 -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-mo
Read more →MTVAGemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals Ann Arbor, Mich., December 30 2019 The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceutic
Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals Ann Arbor, Mich., December 30 2019 The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours
Read more →MTVANovel Treatments for Neurodegenerative and Cardiometabolic Conditions Multi-modal, disease-modifying therapies SAFE HARBOR STATEMENT This presentation includes forward-looking statements within the meaning of Section 27A
Ltd. to advance gemcabene, into the Chinese market Provides back end milestone and royalty payments to NeuroBo if certain development and commercialization milestones are met Pre-merger Gemphire stockholders received contingent value rights (CVRs) entitling them to certain cash p
Read more →MTVAGemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals Ann Arbor, Mich.
Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals Ann Arbor, Mich., December 6, 2019 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent in
Read more →MTVANovel Treatments for Neurodegenerative Conditions Multi-modal, disease-modifying therapies DISCLAIMER Forward-Looking Statements All statements in this presentation other than statements of historical facts, including st
1 Novel Treatments for Neurodegenerative Conditions Multi-modal, disease-modifying therapies DISCLAIMER Forward-Looking Statements All statements in this presentation other than statements of historical facts, including statements regarding the proposed transaction with Gemphire
Read more →MTVAGemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update LIVONIA, Mich., August 9, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for
Read more →MTVAGemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo's Clinical
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo's Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candid
Read more →MTVAGemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPL
Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE)
Read more →MTVAGemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the
Read more →MTVASafe Harbor Statement This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
J Am Coll Cardiol. 2018;72(3):330 43; company presentations 25-35% CV Risk 65-75% 25 Absolute Levels of TGs In INDIGO-1 538 mg/dL 333 mg/dL 200 300 400 500 600 700 Baseline Week 2 Week 6 Week 10 End of Study Median Plasma Triglycerides (mg/dL) Median Plasma Triglycerides Placebo
Read more →MTVAGemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update LIVONIA, Mich., December 3, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardio
Read more →MTVAGemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update LIVONIA, Mich., November 8, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for card
Read more →MTVAGemphire Therapeutics Inc. Condensed Statements of Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) For the Three Months Ended For the Six Months Ended June 30
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update LIVONIA, Mich., August 13, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for card
Read more →MTVAGemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD LIVONIA, Mich., Aug. 10, 2018 Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic d
Read more →MTVAGemphire Provides Update On Development of Gemcabene FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends l
Gemphire Provides Update On Development of Gemcabene FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional flexibility
Read more →MTVAGemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.
Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc. LIVONIA, Mich., August 6, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic di
Read more →MTVAADVANCING CARDIOVASCULAR AND NASH OPPORTUNITIES INDIGO-1 Trial Top-Line Results June 28th, 2018 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of Section 27A of the Securit
(37) & Canada (2) Demographics & Baseline Characteristics Treatment Groups Were Comparable Demographically 600 mg 5 Defined as LDL-C 100 mg/dL and TGs 200 mg/dL Placebo n=31 Gemcabene 300 mg n=30 Gemcabene n=30 Demographics Age (Mean): years 54.6 51.5 56.3 Gender: % Female (n) 38
Read more →MTVAwho are diagnosed with NAFLD and abnormal liver function as assessed by liver transaminases. o The primary endpoint is a measure of the change in serum alanine transaminase (ALT), an enzyme that serves as a biomarker of
Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update LIVONIA, Mich., May 08, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiome
Read more →MTVADiagnostics), Molecular Templates, Tetraphase Pharmaceuticals, BioTrove (acquired by LifeTechnologies), Biocius Life Sciences (acquired by Agilent), and nanoMR (acquired by DNAe). Prior to becoming a venture investor, Dr
Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer LIVONIA, Mich., May 3, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therap
Read more →MTVAGemphire Therapeutics Inc. Condensed Statements of Comprehensive Loss (in thousands, except per share amounts) Year Ended Three Months Ended December 31
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March. 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical compa
Read more →MTVAAbout Gemphire Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatme
Gemphire Announces Pricing of $22 Million Public Offering of Common Stock LIVONIA, Mich., February 8, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders,
Read more →MTVACondensed Statements of Comprehensive Loss (in thousands, except per share amounts) For the Three Months Ended For the Nine Months Ended September 30
Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results
Read more →MTVA(NAFLD). Gemcabene has demonstrated proof of concept efficacy for NASH in the STAM™ model developed at SMC Laboratories in Tokyo, Japan. Gemcabene has been tested as monotherapy and in combination with statins and
Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit COBALT-1 results show significant LDL-C lowering for FH patients, including a mean reduction in LDL-C of 39% in the HeFH population Gemcabene demonstrates novel mechanism to significantly lower LDL-C in
Read more →MTVAincluding: the success and timing of Gemphire's regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to Gemphire's clinical trial designs and regulatory pathways;
Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development New analysis of data show clinically meaningful reductions in LDL-C and hsCRP across multiple trials and confirms support to advance gemcabene into Phase 3 End of Phase 2 meetings planned for early
Read more →MTVACondensed Statements of Comprehensive Loss (in thousands, except per share amounts) For the Three Months Ended For the Six Months Ended June 30
Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update Gemcabene Successful in Phase 2 COBALT-1 HoFH Trial Gemcabene Hits Primary Endpoint in Phase 2 ROYAL-1 Hypercholesterolemia Trial LIVONIA, Mich., Aug. 14, 2017 Gemphire Therapeutics Inc. (NA
Read more →MTVAproviding new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patien
Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients Gemcabene met the primary endpoint and demonstrated a statistically significant lowering in LDL-C Company to host conference call at 8:00 am ET, Monday, August 7, 2017 LIVONI
Read more →MTVAability to successfully market and distribute its product candidate, if approved; Gemphire's ability to obtain and maintain its intellectual property protection; and other factors discussed in the "Risk Factors" section
Gemphire Enters into $15 Million Term Loan Agreement with Silicon Valley Bank LIVONIA, Michigan, July 25, 2017 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced that it has entered into a loan and security agreement with Silicon Valley Bank for a term loan of up to $1
Read more →MTVAwith statins and other drugs in 903 subjects across 19 Phase 1 and Phase 2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability. About Gemphire Gemphire is a clinical-stage biophar
Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients Gemcabene achieves primary endpoint for LDL cholesterol in phase 2b HoFH trial Company to host conference call at 4:30 pm ET today LIVONIA, Michigan, June 28, 2017 -- Gemphire Therapeutics
Read more →MTVAGemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch Livonia, Michigan
Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch Livonia, Michigan, May 30, 2017 (NEWSWIRE) Gemphire Therapeutics Inc. (Nasdaq:GEMP) announced today that Mina Sooch, President, CEO, and Director of the Company has resigned for personal reasons
Read more →MTVAGemphire Therapeutics Inc. Balance Sheet Data (in thousands) March 31
Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update LIVONIA, Michigan, May 9, 2017 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic
Read more →MTVAGemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update Announces Date for 2017 Annual Meeting of Stockholders Conference Call and Live Webcast, Today at 4:30 Eastern Time
Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update Announces Date for 2017 Annual Meeting of Stockholders Conference Call and Live Webcast, Today at 4:30 Eastern Time LIVONIA, Michigan, March 15, 2017 Gemphire Therapeutics Inc. (NASDAQ: GEMP),
Read more →MTVAGemphire Therapeutics Announces $12.5 Million Financing
Gemphire Therapeutics Announces $12.5 Million Financing LIVONIA, Mich., March 10, 2017 Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today
Read more →MTVAAdvancing a class on top of statins February 2017 Safe Harbor Statement 2 This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
Advancing a class on top of statins February 2017 Safe Harbor Statement 2 This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except
Read more →MTVAGEMPHIRE ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE LIVONIA, Mich., NOV 2, 2016 Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developin
GEMPHIRE ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE LIVONIA, Mich., NOV 2, 2016 Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslip
Read more →Competitive Position
How MTVA ranks across every disease it competes inCompetitive Position is a premium feature
See how MTVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial